Pfizer CEO Albert Bourla used unequivocal language during the company's August earnings call to reassure investors on dividend safety. When Morgan Stanley analyst Terence Flynn asked directly what would trigger a dividend cut, Bourla said management is "extremely confident" in its ability to maintain the dividend "even through the most stretched scenarios" the company models. He emphasized the point with force: "I want to once and for all make that clear to all" that Pfizer would maintain its dividend and eventually resume growing it.
Interim CFO Cecile Guegan reinforced the message three times during her financial presentation, stressing that the company would continue paying dividends while investing in growth.
Investor anxiety about Pfizer centers on an impending patent cliff—multiple key products are losing exclusivity, with anticipated revenue declines. But the company's growth portfolio is already offsetting these losses faster than initial projections suggested. Pfizer has beaten revenue estimates in nine of the last 10 quarters and exceeded adjusted earnings estimates in all of the past 10 quarters.
The driver: acquisitions. Seagen therapies contributed one-fourth of operating revenue growth in Q2 and delivered 21 percent year-over-year revenue growth. Nurtec, the Biohaven migraine drug, jumped 17 percent year-over-year. New products including weight-loss drug berobenatide from the Metsera acquisition are critical to the company's target of high single-digit compound annual revenue growth over the next five years.
Pfizer's balance sheet strength adds credibility to dividend commitments. The company maintains a sizable cash stockpile and currently trades at a forward dividend yield exceeding 6.2 percent—placing it among a select few S&P 500 members offering yields at that level. For income-focused portfolios, the combination of clear management conviction and a yield significantly above the broader market warrants a closer look.
